Literature DB >> 16305054

Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors.

Christopher P Gale1, T Simon Futers, Lucinda K M Summers.   

Abstract

Advanced glycation endproducts (AGEs) form at an accelerated rate in diabetes and contribute to the development of macrovascular disease. Their precursors are detoxified by the glyoxalase system. Perturbations of the glyoxalase-1 gene may alter AGEs' interactions and affect pro-thrombotic factors. We screened the glyoxalase-1 gene for mutations and measured pro-thrombotic markers in 537 subjects from 89 healthy probands. Common single nucleotide polymorphisms (SNPs) were identified at positions -7 (C to T) and 20203 (C to A) from the translation start site. These SNPs were in Hardy-Weinberg equilibrium (CC=105, CA=266, AA=148; p>0.05; CC=126, CT=279, TT=114; p>0.05, respectively) and in linkage disequilibrium (D=27%, p<0.01), with mutant allele frequencies of 48% and 52% respectively. A significant association was found between SNPs at position 20203 and PAI-1 antigen concentrations and -7 and factor XIII A2B2 complex (p=0.001 and p=0.042). After Bonferroni correction a significant association remained between the SNP at 20203 and PAI-1 concentrations (p=0.005), and after adjustment for pedigree the association accounted for 1.3% of its heritability (p=0.04). No significant associations were found for SNP -7 T to C and factor VII activity, tPa concentrations, fibrinogen concentrations or factor XIII concentrations and SNP 20203 C to A and factor VII concentrations, PAI-1 concentrations, tPa concentrations or fibrinogen concentrations. Common variants in the glyoxalase-1 gene are associated with some pro-thrombotic factors, account for part of their heritability in healthy pedigrees and may alter susceptibility to macrovascular complications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16305054     DOI: 10.3132/dvdr.2004.004

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  8 in total

Review 1.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

Review 2.  The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Circ Res       Date:  2010-03-19       Impact factor: 17.367

3.  Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in Type 2 diabetes.

Authors:  J C Wu; X H Li; Y D Peng; J B Wang; J F Tang; Y F Wang
Journal:  J Endocrinol Invest       Date:  2011-07-07       Impact factor: 4.256

4.  Protection from diabetes-induced peripheral sensory neuropathy--a role for elevated glyoxalase I?

Authors:  M M Jack; J M Ryals; D E Wright
Journal:  Exp Neurol       Date:  2011-12-19       Impact factor: 5.330

5.  Distribution of glyoxalase I polymorphism among Zuni Indians: the Zuni Kidney Project.

Authors:  Guenet H Degaffe; David L Vander Jagt; Arlene Bobelu; Jeanette Bobelu; Donica Neha; Mildred Waikaniwa; Philip Zager; Vallabh O Shah
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

Review 6.  The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality.

Authors:  Jyotiska Chaudhuri; Yasmin Bains; Sanjib Guha; Arnold Kahn; David Hall; Neelanjan Bose; Alejandro Gugliucci; Pankaj Kapahi
Journal:  Cell Metab       Date:  2018-09-04       Impact factor: 27.287

Review 7.  The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC).

Authors:  Marcus Hollenbach
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

8.  Common variants in glyoxalase I do not increase chronic pancreatitis risk.

Authors:  Tom Kaune; Marcus Hollenbach; Bettina Keil; Jian-Min Chen; Emmanuelle Masson; Carla Becker; Marko Damm; Claudia Ruffert; Robert Grützmann; Albrecht Hoffmeister; Rene H M Te Morsche; Giulia Martina Cavestro; Raffaella Alessia Zuppardo; Adrian Saftoiu; Ewa Malecka-Panas; Stanislaw Głuszek; Peter Bugert; Markus M Lerch; Frank Ulrich Weiss; Wen-Bin Zou; Zhuan Liao; Peter Hegyi; Joost Ph Drenth; Jan Riedel; Claude Férec; Markus Scholz; Holger Kirsten; Andrea Tóth; Maren Ewers; Heiko Witt; Heidi Griesmann; Patrick Michl; Jonas Rosendahl
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.